Who is sponsoring NCT04488354?

NCT04488354 is sponsored by Calibr, a division of Scripps Research.

What drugs are being tested in NCT04488354?

Interventions in NCT04488354: CLBR001 and SWI019.

What condition does NCT04488354 study?

NCT04488354 studies Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma (SLL), Primary Mediastinal Large B Cell Lymphoma, Transformed Follicular Lymphoma, Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma, Burkitt Lymphoma.

Is NCT04488354 still recruiting?

NCT04488354 is currently completed. Last updated 8 April 2026.

Last reviewed 2026-04-08 · How we verify

NCT04488354

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Completed Phase 1 Last updated 8 April 2026

What this trial tests

Phase 1 trial testing CLBR001 and SWI019 in Relapsed/Refractory B-cell Lymphomas in 16 participants. Completed in 6 October 2025.

Timeline

21 January 2021

Primary endpoint
6 October 2025

6 October 2025

Quick facts

Lead sponsor	Calibr, a division of Scripps Research
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	16
Start date	21 January 2021
Primary completion	6 October 2025
Estimated completion	6 October 2025
Sites	8 locations across United States

Drugs / interventions tested

CLBR001 and SWI019

Conditions studied

Relapsed/Refractory B-cell Lymphomas — all drugs for Relapsed/Refractory B-cell Lymphomas →
Diffuse Large B-Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B-Cell Lymphoma (DLBCL) →
Follicular Lymphoma (FL) — all drugs for Follicular Lymphoma (FL) →
Chronic Lymphocytic Leukemia (CLL) — all drugs for Chronic Lymphocytic Leukemia (CLL) →

Sponsor

Calibr, a division of Scripps Research — full company profile →

Who can join

18 and older, any sex, with Relapsed/Refractory B-cell Lymphomas or Diffuse Large B-Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

ROR1-targeting switchable CAR-T cells for cancer therapy.
Peng H, Nerreter T, Mestermann K, Wachter J, et al · · 2022 · cited 22× · PMID 35859167 · DOI 10.1038/s41388-022-02416-5
Modular (universal) CAR-T platforms <i>in vivo</i>: a comprehensive systematic review.
Mohammad A, Yurina A, Simonyan T, Chistyakov D, et al · · 2024 · cited 6× · PMID 39712013 · DOI 10.3389/fimmu.2024.1409665
Chemical immunology: Recent advances in tool development and applications.
Shi Y, Bashian EE, Hou Y, Wu P. · · 2024 · cited 5× · PMID 38508196 · DOI 10.1016/j.chembiol.2024.02.006

Verify or expand the search:

Other trials of CLBR001 and SWI019

Trials testing the same drug.

NCT04450069 — CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies · Phase 1 · completed

Other recruiting trials for Relapsed/Refractory B-cell Lymphomas

Currently open trials in the same condition.

NCT06478381 — L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma · Phase 1 · recruiting

Other Calibr, a division of Scripps Research trials

Trials by the same sponsor.

NCT05950906 — Study to Assess PDM608 in Healthy Adult Subjects · Phase 1 · completed
NCT04450069 — CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies · Phase 1 · completed
NCT04077021 — First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer · Phase 1 · terminated
NCT03133676 — A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04488354 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Calibr, a division of Scripps Research
Last refreshed: 8 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04488354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing